scholarly journals Topiramate: Long-Term Maintenance of Weight Loss Induced by a Low-Calorie Diet in Obese Subjects

2004 ◽  
Vol 12 (10) ◽  
pp. 1658-1669 ◽  
Author(s):  
Arne Astrup ◽  
Ian Caterson ◽  
Pierre Zelissen ◽  
Bernard Guy-Grand ◽  
Michele Carruba ◽  
...  
1999 ◽  
Vol 106 (2) ◽  
pp. 179-184 ◽  
Author(s):  
Marian Apfelbaum ◽  
Philippe Vague ◽  
Olivier Ziegler ◽  
Corinne Hanotin ◽  
Florence Thomas ◽  
...  

1999 ◽  
Vol 99 (4) ◽  
pp. 194c
Author(s):  
M Apfelbaum ◽  
P Vague ◽  
O Ziegler ◽  
C Hanotin ◽  
F Thomas ◽  
...  

2002 ◽  
Vol 102 (5) ◽  
pp. 569-577 ◽  
Author(s):  
Peter FABER ◽  
Alexandra M. JOHNSTONE ◽  
Eileen R. GIBNEY ◽  
Marinos ELIA ◽  
R. James STUBBS ◽  
...  

Obesity is commonly associated with a high incidence and prevalence of dyslipidaemia, cardiovascular disease and Type II diabetes. Interestingly, studies have also reported decreased antioxidant levels in obese subjects. This may constitute an independent risk factor in the pathogenesis of coronary artery disease as obese subjects would have a decreased capacity to prevent the oxidative modification of low-density lipoproteins, which is a mechanism suggested as central to the development of atherogenesis. As part of a study to investigate responses to weight loss, we have assessed the effects on GSH status of a decrease in body mass of 5%, either after 6 days of complete starvation or 11 days of a very low calorie diet (2.55MJ/day). There were significant differences between the two groups in the synthesis rate of erythrocyte GSH in response to weight loss. Both the fractional and the erythrocyte synthesis rate of GSH decreased significantly (P<0.01) in the starvation group by 22% and 16% respectively. In contrast, no change in synthesis rates was observed in the very low calorie diet group (P>0.05). Total erythrocyte concentration of GSH was unaffected by the weight loss within both groups. These results suggest that erythrocyte GSH synthesis is depressed in response to a very rapid weight loss induced by fasting. An acute reduction in GSH synthesis in response to a rapid weight loss may constitute a risk factor during periods of increased GSH demands.


1992 ◽  
Vol 56 (1) ◽  
pp. 279S-280S ◽  
Author(s):  
J S Cox ◽  
S N Kreitzman ◽  
A Y Coxon ◽  
J Walls

2018 ◽  
Vol 29 (1) ◽  
pp. 54-60 ◽  
Author(s):  
Kamthorn Yolsuriyanwong ◽  
Komdej Thanavachirasin ◽  
Kimberly Sasso ◽  
Lauren Zuro ◽  
Jessica Bartfield ◽  
...  

BMJ Open ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. e031431
Author(s):  
Simon Birk Kjær Jensen ◽  
Julie Rehné Lundgren ◽  
Charlotte Janus ◽  
Christian Rimer Juhl ◽  
Lisa Møller Olsen ◽  
...  

IntroductionThe success rate of weight loss maintenance is limited. Therefore, the purpose of this study is to investigate the maintenance of weight loss and immunometabolic health outcomes after diet-induced weight loss followed by 1-year treatment with a glucagon-like peptide-1 receptor agonist (liraglutide), physical exercise or the combination of both treatments as compared with placebo in individuals with obesity.Methods and analysisThis is an investigator-initiated, randomised, placebo-controlled, parallel group trial. We will enrol expectedly 200 women and men (age 18–65 years) with obesity (body mass index 32–43 kg/m2) to adhere to a very low-calorie diet (800 kcal/day) for 8 weeks in order to lose at least 5% of body weight. Subsequently, participants will be randomised in a 1:1:1:1 ratio to one of four study groups for 52 weeks: (1) placebo, (2) exercise 150 min/week+placebo, (3) liraglutide 3.0 mg/day and (4) exercise 150 min/week+liraglutide 3.0 mg/day. The primary endpoint is change in body weight from randomisation to end-of-treatment.Ethics and disseminationThe trial has been approved by the ethical committee of the Capital Region of Denmark and the Danish Medicines Agency. The trial will be conducted in agreement with the Declaration of Helsinki and monitored to follow the guidelines for good clinical practice. Results will be submitted for publication in international peer-reviewed scientific journals.Trial registration number2015-005585-32


Sign in / Sign up

Export Citation Format

Share Document